EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Levosimendan bei der Therapie der akuten hamodynamisch bedeutsamen Lungenembolie


Intensivmedizin und Notfallmedizin 43(8): 636-642
Levosimendan bei der Therapie der akuten hamodynamisch bedeutsamen Lungenembolie
Background Right ventricular competence plays a pivotal role in the clinical course of acute pulmonary embolism. A fatal outcome of an event is mainly due to right heart failure. Levosimendan is a calcium sensitizer, which so far has been evaluated in the setting of left heart failure. We describe the effects of levosimendan in the setting of right heart failure due to acute pulmonary embolism. Methods and results We evaluated the hemodynamic effects and the clinical course of 7 patients in whom therapy of acute pulmonary embolism was augmented by levosimendan. All patients showed echocardiographic signs of right ventricular distension; 6 of the 7 patients showed hypotension with a systemic systolic blood pressure of < 90 mmHg. Under therapy with levosimendan 6 of the 7 cases showed a rapid clinical and hemodynamic recovery, characterized by a significant decrease of systolic pulmonary artery pressure and heart rate within the next 12 and 24 hours. Six patients survived the event. Therapy with levosimendan was not discontinued in any patient. Four patients were treated in addition with fibrinolysis, while 3 patients were treated with heparin alone. In none of these patients was an escalation in therapy required. Conclusion This is a first report of a successful use of levosimendan in the setting of acute right heart failure due to acute pulmonary embolism. Randomized prospective trials are necessary to validate these acute results, to check for side effects and prognostic implications in a larger number of patients, before this kind of therapy can be recommended for regular therapy.

(PDF 0-2 workdays service: $29.90)

Accession: 012988891



Related references

Thrombolytische therapie der akuten lungenembolie. Herz 30(4): 261-268, 2005

Zur Pathogenese und Therapie des akuten Ekzems und der akuten Dermatitis,. Arch Dermatol U Syph 163(2): 295-325, 1931

Ausschlussidiagnostik der akuten Lungenembolie. Intensiv und Notfallbehandlung 31(4): 177-183, 2006

Diagnostik und Management der akuten Lungenembolie. Herz 32(1): 35-41, 2007

Leitliniengerechtes management der akuten Lungenembolie. Intensiv und Notfallbehandlung 31(4): 184-192, 2006

Akute Lungenembolie: Ein neuer Score zur Quantifizierung der akuten Rechtsherzbelastung. Intensivmedizin und Notfallmedizin 40(2): 130-137, 2003

Therapie des akuten Nierenversagens: Fussangeln der Therapie. Intensivmedizin und Notfallmedizin 40(5): 361-368, 2003

Chirurgische therapie der fulminanten lungenembolie. Herz 30(4): 269-273, 2005

Aktuelle Therapie und Sekundarpravention der Lungenembolie. 2013

Therapie der Lungenembolie - Evidenz oder Empirie?. 2007